Reason for request
- Re-assessment of the improvement in actual benefit at the applicant’s
Clinical Benefit
Clinical Added Value
| minor |
Au regard des nouvelles données disponibles, l’ipilimumab (YERVOY) conserve son amélioration du service médical rendu mineure (ASMR IV) dans la stratégie thérapeutique. |
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
m96k9VGdYmfCTepL
